BAY1841788 / darolutamide (ODM-201)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metastatic Hormone-sensitive Prostate Cancer

Drug Information

Target Indication

Metastatic Hormone-sensitive Prostate Cancer

Clinical Trial

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Related Pipeline

Acute Coronary Syndrome

Overactive Bladder

Pneumonia, Bacterial

Chronic Kidney Disease

Colorectal Neoplasms